AES 2021 Symposium Summary of Results from the "X-TOLE" Study FRIDAY, DECEMBER 3, 2021 NASDAQ: XENE www.xenon-pharma.com XEN1101 Next-Gen KV7 Channel Opener ▪ Only-in-class KV7 potassium channel modulator to treat adult focal seizures ▪ Novel MOA for rational polypharmacy ▪ Designed to address limitations of first-gen KV7 modulator, ezogabine • Higher in vitro and in vivo potency • PK TID → QD • Lacks the chemical properties that could form pigmented dimers ▪ Improved seizure reduction ▪ Potential to treat ...

AES 2021 Symposium Summary of Results from the "X-TOLE" Study FRIDAY, DECEMBER 3, 2021 NASDAQ: XENE www.xenon-pharma.com XEN1101 Next-Gen KV7 Channel Opener ▪ Only-in-class KV7 potassium channel modulator to treat adult focal seizures ▪ Novel MOA for rational polypharmacy ▪ Designed to address limitations of first-gen KV7 modulator, ezogabine • Higher in vitro and in vivo potency • PK TID → QD • Lacks the chemical properties that could form pigmented dimers ▪ Improved seizure reduction ▪ Potential to treat ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sherry Aulin – Chief Financial Officer Ian Mortimer – President and Chief Executive Officer Chris Kenney – Chief Medical Officer Chris Von Seggern – Chief Commercial Officer Conference Call Participants Andrew Tsai – Jefferies Brian Abrahams – RBC Capital Markets Marc Goodman – SVB Leerink Eddie Hickman – Guggenheim Serge Belanger – Needham and Company Operator Good day. And thank you ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other j ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants Ian Mortimer - President and CEO Simon Pimstone - Executive Chair of the Board Chris Von Seggern - Chief Commercial Officer Sherry Aulin - Chief Financial Officer Jodi Regts - IR Conference Call Participants Paul Matteis - Stifel Nicolaus Marc Goodman - SVB Leerink Andrew Tsai - Jefferies Yatin Suneja - Guggenheim Securities Tim Lugo - William Blair David Hoang - SMBC Nikko Serge Belange ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisd ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Company Participants Simon Pimstone - CEO Ian Mortimer - President and CFO Sherry Aulin - VP, Finance Jodi Regts - IR Conference Call Participants Laura Chico - Wedbush Securities Paul Matteis - Stifel Marc Goodman - SVB Leerink Tim Lugo - William Blair Andrew Tsai - Jefferies Serge Belanger - Needham Eddie Hickman - Guggenheim Antonia Borovina - Bloom Burton David Koh - SMBC Operator Ladies and gentlemen, than ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other juris ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Representatives Simon Pimstone - Chief Executive Officer Ian Mortimer - President, Chief Financial Officer Sherry Aulin - Vice President, Finance Jodi Regts - Investor Relations Conference Call Participants Paul Matteis - Stifel Andrew Tsai - Jefferies Marc Goodman - SVB Leerink Kenneth Shields - Wedbush Eddie Hickman - Guggenheim Serge Belanger - Needham & Company Tim Lugo - William Blair Antonia Boro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisdictio ...